shutterstock_619078730_melinda_nagy

Melinda Nagy / Shutterstock.com

8 April 2021Big PharmaMuireann Bolger

UK govt’s £20m fund for life sciences opens for applications

The UK government’s £20 million fund aimed at growing life sciences manufacturing is now open for applications, it confirmed today, April 7.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

More on this story

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

More on this story

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB